Clinical Trials · NCT05035095
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 667
- Start date
- Sep 2021
- Locations
- 56 sites, 9 countries
- Primary endpoint
- Percentage Change in Body Weight